Board summary
Key figures
48,728
Registered population
53.0% aged 18–64
30.6%
Aged 65+
ICB 19.9% · England 17.9%
3.1%
Ethnic minority (non-White)
1.1% Asian · England 9.6%
2.9%
In IMD quintile 1
ICB 17.1% · England 21.0%
~1,376
Core20 residents (est.)
Resident basis; registered basis ~1,461 · see page 3
10,087
Hypertension register
+7.60% in 3 yrs · England +5.60%
492
SMI register
38.6% of Dover's
1,606
COPD register
Reviews +3.72% in 3 yrs
Forecast to 2030
12,222
Hypertension patients, 2030
+2,135 on today
72.0%
QRISK ≥20% on statins, 2030
+4.63pp over 3 yrs
7.8%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
Asthma reviews trail England alongside high prescribing.
Annual asthma reviews reach 60.4% (England 65.7%, Dover 62.0%), leaving about 1,300 of 3,320 patients unreviewed alongside 2,035 items per 1,000 aged 5-19.
QRISK lipid therapy lags with higher unit cost.
Lipid-lowering therapy for QRISK ≥ 20% is 61.5% (England 63.6%), while 88,342 lipid-modifying items cost £2.40 each, or £47,705 more than England's £1.86 rate.
Heart failure reviews exceed local and national rates.
Annual heart failure reviews reach 79.7% (England 78.5%, Dover 71.2%), rising +19.4% over three years (England +8.7%, Dover -7.9%).
Population, age and ethnicity
With 30.6% aged 65 and over, an older population could increase local care demand
Across 48,728 registered patients, 30.6% (14,937) are aged 65+, well above Dover (24.2%), NHS Kent and Medway ICB (19.9%) and England (17.9%). Working-age adults (18-64) make up 53.0% (25,816), below Dover (56.8%), the ICB (59.5%) and England (62.7%), while children (0-17) represent 16.4% (7,975). List size is projected to grow +3.6% by 2030 (Dover +5.3%, ICB +6.0%, England +2.3%; unverified methodology). Census resident data shows 96.8% White (Dover 94.9%, ICB 88.6%, England 81.1%) and 1.1% Asian / Asian British (Dover 2.1%, ICB 4.7%, England 9.6%), with an estimated 3.1% non-White ethnic minority share.
Age profile
65+: ICB 19.9%, England 17.9%
Ethnicity
Older people · falls rows are Dover local-authority (LA) data, not PCN
| Measure | Local | South East | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Dover LA) | 1,557 | 2,018 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 85.9% | 82.2% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 58.8% | 57.8% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Dover LA) | 886 | 981 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Dover LA) | 25.9 | 14.0 | 14.8 | 2022‑24 |
Deprivation and Core20
Only 2.9% of registered patients live in Core20 areas, unevenly distributed across practices
Core20 patients—living in England's most deprived 20% of areas—comprise 2.9% of registered patients, below Dover (22.9%), NHS Kent and Medway ICB (17.1%), and England (21.0%). Practice estimates sum to 1,461 patients, while resident decile estimates total 1,376, reflecting differing population bases. Distribution is uneven: The New Golf Road Surgery has the highest share (6.3%, 166 estimated patients), whereas Balmoral Surgery holds the largest volume (5.1%, 590 estimated patients); Sandwich Medical Practice records 0.0%. Outreach should balance volume-led clinical recall with targeted community engagement.
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
492
SMI register
1.00% recorded prevalence
332
Learning disability register
0.68% recorded prevalence
26
Care homes, 610 beds
In the PCN catchment
10.3%
Provide unpaid care
Dover, Census 2021
Recorded registers include 492 patients with severe mental illness (1.0% vs Dover 1.1%, ICB 0.9%, England 1.0%) and 332 with learning disabilities (0.7% vs Dover 0.8%, ICB 0.6%, England 0.6%). The catchment contains 26 care homes with 610 beds. Dover's 10.3% unpaid care rate and 8 rough sleepers (2025) cannot be extrapolated to PCN lists.
Severe mental illness: physical health checks
Across 492 patients on the SMI register (1.0%), 84.5% received a blood pressure check (England 83.4%), but BMI recording reached 78.4% (England 82.1%), while alcohol recording was 80.7% (England 81.8%). Missing elements cannot imply completed checks.
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
10,087
Hypertension register
+7.60%
Register growth, 3 yrs
Dover +6.06% · England +5.60%
+1.43pp
BP control, under 80
≤140/90 · −0.05pp aged 80+
+2,135
More patients by 2030
Forecast 12,222 (23.83%)
Hypertension case-finding and control
Recorded hypertension prevalence is 20.6% (10,087 patients), above Dover (18.3%), NHS Kent and Medway ICB (16.2%) and England (15.2%), consistent with an older demographic where 30.6% are aged 65+. For patients aged 80 and over, blood pressure control to <= 150/90 mmHg is 78.0%, below Dover (78.7%), the ICB (78.3%) and England (81.2%), with three-year change trailing at -0.1% (England +2.2%). Denominators include personalised care adjustments, and crude prevalence is not age-adjusted. Lower blood pressure control among older patients than England may indicate scope to review recall and titration protocols for hypertensive patients aged 80 and over.
Lipids and statins
Among patients with QRISK ≥ 20%, 61.5% receive lipid-lowering therapy, below Dover (62.6%) and England (63.6%), but above the ICB (61.4%). Statin coverage in diabetes aged 40+ without cardiovascular disease is 73.1% (England 73.2%). Lower high-risk lipid coverage than England may suggest scope for primary prevention recall.
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 88,342 | £2.40 | £1.90 | £1.86 | £212,021 |
| Cardiovascular (all), 2025 | 117,581 | £4.19 | £3.57 | £3.33 | £492,664 |
In 2026, lipid-modifying drugs cost £2.40 per item across 88,342 items, exceeding Dover (£2.27), NHS Kent and Medway ICB (£1.90) and England (£1.86). The PCN spends £47,705 more than at England's unit cost. Higher unit costs than benchmarks may indicate scope to review lipid-modifying formulary choices.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
+3.82%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
+7.41%
Asthma prevalence, PCN 3-yr % change
Asthma prevalence is 7.1% (3,320 patients; England 6.6%) and COPD prevalence is 3.3% (1,606 patients; England 1.9%). Annual asthma reviews reached 60.4% (England 65.7%), leaving about 1,300 unreviewed patients (1,315 by calculation), while COPD reviews reached 74.1% (England 76.4%). Paediatric asthma prescribing reached 2,035 items per 1,000 aged 5–19 (England 1,488), yet second-hand smoke recording for ages 6–19 reached 71.0% (254 patients; England 78.8%). High prescribing alongside lower review rates could reflect reliance on reliever therapy, which local prescribing audit would test.
Cancer register and children's immunisation
Crude cancer prevalence is 6.4% (3,118 patients; England 3.8%), which is consistent with an older age profile (30.6% aged 65+, England 17.9%). Childhood immunisation exceeds benchmarks at 24 months (MMR1 96.1%, 6-in-1 98.7%), but age-5 boosters trail the 95.0% target: MMR2 reaches 93.1% (a 1.9 pp drop from MMR1) and the 4-in-1 booster is 90.1% (below target by 4.9 pp).
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
55.6%
Kent and Medway ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~1,630
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Kent and Medway ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Breast | 82.1% | 85.4% | 23% | 1,509 |
| Prostate | 54.4% | 53.2% | 37% | 1,435 |
| Lung | 29.4% | 33.8% | 21% | 1,109 |
| Bowel | 48.2% | 47.0% | 29% | 1,013 |
| Skin cancer | 87.5% | 87.8% | 23% | 562 |
In 2022, 55.6% of cancers with a known stage in NHS Kent and Medway ICB (4,661 of 8,384) were diagnosed at stage 1 or 2, in line with England (55.3%) but below the 75.0% national ambition by 19.4 pp. Reaching 75.0% would require an estimated 1,627 extra early diagnoses across the ICB. Cancer staging was not captured at PCN level and excludes unstageable cases (63.6% known-stage coverage, 8,384 of 13,189). In DEAL & SANDWICH PCN, breast screening reaches 72.1%, while The New Golf Road Surgery records 66.1% (England 69.9%). Lower practice screening coverage may delay presentation, reinforcing the need to review local uptake alongside wider system pathway improvements.
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
In July 2026 (provisional), East Kent Hospitals University NHS Foundation Trust achieved 70.0% against the 85.0% 62-day standard, behind the ICB (75.9%) and England (71.2%), while East Sussex Healthcare NHS Trust achieved 67.0%. For the 28-day faster diagnosis standard (75.0%), the trust reached 71.3% (ICB 76.8%, England 79.3%), though it met the 31-day standard at 96.7% (standard 96.0%). For diagnostics in July 2026, 63.0% of non-obstetric ultrasound and 47.6% of MRI patients waited 6+ weeks at the trust (England 19.6% and 21.4%). Provider waiting times and diagnostic backlogs describe system capacity rather than PCN performance, but require ongoing clinical safety-netting.
| Pathways within standard (%) | East Kent | East Sussex Healthcare | Mid and South Essex | Kent and Medway ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 71.28 | 84.20 | 67.45 | 76.78 | 79.32 |
| 31-day treatment (96%) | 96.67 | 98.19 | 81.88 | 95.84 | 92.50 |
| 62-day referral to treatment (85%) | 70.01 | 67.04 | 50.25 | 75.93 | 71.16 |
| Diagnostic waits over 6 weeks (%) | East Kent | East Sussex Healthcare | Mid and South Essex | England |
|---|---|---|---|---|
| MRI | 47.58 | 6.48 | 23.35 | 21.40 |
| CT | 37.45 | 0.48 | 6.07 | 9.92 |
| Echocardiography | 14.17 | 21.94 | 65.05 | 28.48 |
| Colonoscopy | 9.58 | 0.74 | 64.09 | 30.83 |
| Gastroscopy | 22.16 | 0.31 | 59.76 | 29.02 |
| All 15 DM01 tests | 48.38 | 5.27 | 41.54 | 23.14 |
| Community services activity | Kent residents | Kent and Medway ICB |
|---|---|---|
| Care contacts | 210,170 | 254,055 |
| Referrals | 59,360 | 68,085 |
| Patients with a contact | 60,605 | 72,060 |
Community services (residents of Kent), Jun 2026 (provisional). In the community services dataset for June 2026 (provisional), adults aged 65+ accounted for 65.8% of contacts among Dover local authority residents (138,250 of 210,170 total contacts). Community service activity is captured solely for borough residents and was not captured for DEAL & SANDWICH PCN or individual practices. Community health activity in Dover is heavily concentrated among older residents, indicating substantial local community support needs.
Practice variation and patient experience
Practice variation and patient experience
In 2025/26, QOF vaccination achievement spans 24.6 pp, from 53.3% at The Cedars Surgery to 77.9% at St Richards Road Surgery. Overall QOF achievement ranges from 88.7% at Sandwich Medical Practice to 97.3% at Balmoral Surgery. Personalised care adjustment rates across all domains vary from 5.9% at Sandwich Medical Practice to 16.0% at Balmoral Surgery.
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| New Golf Road | 134 | 6.3 | 87.0% | 73.3% | 90.1% |
| The Cedars Surgery | 103 | 3.1 | 56.0% | 77.9% | 80.9% |
| Sandwich Medical | 93 | 0.0 | 42.2% | 63.6% | 77.3% |
| Balmoral Surgery | 114 | 5.1 | 44.3% | 68.2% | 74.5% |
| St Richards Road | 118 | 3.4 | 44.9% | 67.7% | 73.7% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
Thirteen of 25 tracked measures trail England's three-year change, led by dementia
Across 25 tracked indicators, 13 trail England's three-year change. The widest relative lags appear in dementia register prevalence, which fell 0.9% (England +6.0%), breast screening coverage at +3.1% (England +8.4%), and statins in diabetes without CVD, which fell 1.5% (England +2.1%). Conversely, heart failure reviews rose +19.4% over three years (England +8.7%) to 79.7% (England 78.5%), and QRISK ≥ 20% lipid therapy grew +8.1% (England +6.2%). Trailing trends may indicate recall or review gaps rather than lower clinical need, which local practice audits would test.
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
Dementia register
Breast screening (53-70)
Diabetes statin (no CVD)
BP control, 80+
Hypertension BP reading
Heart failure reviews
QRISK statin treatment
Cervical screening
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Dover | Asset | PCN | Dover |
|---|---|---|---|---|---|
| Care homes (catchment) | 26 (610 beds) | n/a | Schools (catchment) | 56 | n/a |
| Children's centres | 2 | 7 | Places of worship | 70 | 106 |
| Libraries | 4 | 5 | Food banks (VCS) | n/a | 2 |
| Homelessness support (VCS) | n/a | 1 | Day centres (VCS) | 1 | 4 |
| Carers support groups (VCS) | 1 | 4 | Primary schools (LA maintained) | 9 | 19 |
| Primary academies | 11 | 21 | Special schools | 1 | 1 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Structured asthma review and prescribing recall
Asthma reviews reach 60.4% (Dover 62.0%, England 65.7%) across 3,320 patients, leaving 1,315 (about 1,300) unreviewed, while age 5–19 prescribing is 2,035 per 1,000 (England 1,488). For discussion: practices could run structured asthma recall combining annual reviews, second-hand smoke recording (71.0% vs 78.8% England) and inhaler checks. Moderate effort to run.
Evidence base: the annual asthma review is the process gap between the register and outcomes.
Policy anchor: Core20PLUS5 chronic respiratory disease priority.
Option 2
Lipid therapy recall and formulary review
QRISK ≥ 20% lipid therapy is 61.5% (Dover 62.6%, England 63.6%) and diabetes statins fell 1.5% (England +2.1%), while lipid-modifying drugs cost £2.40 per item (England £1.86), or £47,705 more across 88,342 items. For discussion: clinical pharmacists could combine high-risk lipid and diabetes statin recall with a lipid-modifying formulary review. Moderate effort to run.
Option 3
Hypertension control audit for aged 80+
Across 10,087 hypertension patients (20.6%; England 15.2%), aged 80+ blood pressure control is 78.0% (Dover 78.7%, England 81.2%), and three-year change fell 0.1% (England +2.2%). For discussion: practices could audit hypertensive patients aged 80+ above 150/90 mmHg or missing checks (89.1% vs 90.0% England), aligning care-home monitoring. Low cost, quick to run.
Evidence base: the hypertension register is the cohort for case-finding, blood-pressure control and AF anticoagulation; its size and growth set the workload those interventions must cover, and a shortfall in control shows up later as emergency admission.
Policy anchor: Core20PLUS5 (hypertension case-finding and optimal management); NHS CVD ambitions to 2029 on detection, treatment to target and statins for high-risk patients (CVDPREVENT).
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Anticipatory older adult care planning (p2) | Aged 65+ | Neighbourhood health framework · NHS vaccination strategy | PCN |
| Two-track Core20 outreach (p3) | Core20 cohort (IMD quintile 1) | Core20PLUS5 · 10YHP equity test | PCN |
| Systematic SMI physical health checks (p4) | SMI register with a BMI recorded in the last 12 months | MHIS · From Harm to Hope | PCN |
| Hypertensive patient recall audit (p5) | Last BP reading of patients (80+ yrs with hypertension) in the last 12 months is <= 150/90 mmHg (denominator incl. PCAs) | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Pre-school booster recall catch-up (p6) | 4-in-1 pre-school booster (DTaP/IPV) coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Targeted breast screening recall (p7) | Breast screening coverage: aged 53 to 70 years old | — | Practice |
| Option 1 · Structured asthma review and prescribing recall (p12) | Asthma register · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) · Asthma management items prescribed per 1000 5-19 Population | Core20PLUS5 respiratory | PCN |
| Option 2 · Lipid therapy recall and formulary review (p12) | Cost per item for Lipid-regulating drugs 2026 · Count of Items prescribed for Lipid-regulating drugs 2026 · Patients with QRISK ≥ 20% treated with lipid lowering therapy | — | PCN |
| Option 3 · Hypertension control audit for aged 80+ (p12) | Hypertension register · Hypertension: QOF prevalence · Last BP reading of patients (80+ yrs with hypertension) in the last 12 months is <= 150/90 mmHg (denominator incl. PCAs) | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | ICB | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
